Researchers at Hebrew University of Jerusalem have identified two inclusion bodies, JUNQ and IPOD, with opposing effects on protein aggregation. Aggregation in JUNQ can lead to toxicity, while aggregation in IPOD is protective, suggesting a new potential strategy for designing therapeutics for neurodegenerative diseases.
Researchers used RNA interference technology to identify hundreds of molecular targets linked to HD toxicity, including RRAS signaling as a pathologic feature. The study provides a roadmap for discovering new therapies and offers hope for treating the devastating disease.
Treatment with SIRT2 inhibitor AK-7 reduced neurodegeneration and behavioral symptoms in two animal models of Huntington's disease. The study showed improved motor function, brain structure preservation, and extended survival in treated animals compared to untreated controls.
Researchers at the University of Montreal have identified a chemical chain that causes neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis and dementia. Increasing another cell chemical called progranulin has been shown to reduce neuron death by combating mutant huntingtin protein accumulation.
Researchers found that immune cells, including microglia, are defective in their ability to migrate in Huntington's disease. The study suggests that changes in immune cell function may underlie some of the symptoms of HD.
Researchers have designed a compound that suppresses symptoms of Huntington's disease in mice by targeting mitochondria, potentially leading to new treatments for neurodegenerative diseases. The synthetic antioxidant XJB-5-131 improves mitochondrial function and enhances neuron survival.
A gene called spastin plays a critical role in axon regeneration, which was found to be shut down by a mutation in the gene. The researchers used fruit flies as a model organism and observed that severed axons regrew normally when the gene was present.
A BUSM study has pinpointed the two main areas of the brain most severely impacted by Huntington's disease, the striatum and outer cortical regions. The research also found significant variation in the extent of cell death across individuals, with some experiencing severe damage while others appear virtually normal.
Scientists have discovered a way to quantify mutant huntingtin protein in immune cells isolated from a normal blood draw, which shows significant correlation with disease symptom severity. This breakthrough could enable the development of non-invasive biomarkers for Huntington's disease.
Researchers found that individuals with Huntington's gene mutation exhibit increased learning efficiency, which is more pronounced in those with stronger mutations. This paradoxical effect suggests that neurodegenerative changes can lead to improved cognitive function.
The Georgetown University Medical Center has established a first-of-its-kind center for treating and researching Huntington's disease. The center will provide comprehensive care, education, and research to patients and families affected by the disease.
A new guideline published by the American Academy of Neurology recommends several treatments for people with chorea, a symptom of Huntington's disease that can make everyday activities challenging. The guideline suggests that medications such as tetrabenazine, riluzole, and amantadine may be helpful in treating chorea.
Researchers at the University of California, San Diego have identified two key regulatory proteins critical to clearing away misfolded proteins that accumulate and cause neurodegeneration in Huntington's disease. PGC-1alpha and TFEB provide a new therapeutic target for treating the disease, offering hope for its treatment.
Researchers derived iPS cells from patients with genetic forms of Parkinson's and found common signs of distress in neurons, including abnormalities in mitochondria. The cells' responses to treatments depended on the type of Parkinson's each patient had.
Researchers at Gladstone Institutes have generated a human model of Huntington's disease from patient skin cells, providing a more accurate and faithful replication of the disease. This new model will help scientists better understand the development of Huntington's and identify potential therapeutic approaches.
Cedars-Sinai researchers created a laboratory model for Huntington's disease using induced pluripotent stem cells from patients' skin cells. The 'disease in a dish' model allows scientists to test therapies directly on human Huntington's neurons, offering a new pathway to identifying treatments.
Scientists successfully converted skin cells from a patient with severe Huntington's disease into neurons that degenerate like those affected by the fatal disorder. This breakthrough enables researchers to test potential drug therapies on human brain cells in a dish.
A team of scientists has generated a human model of Huntington's disease directly from the skin cells of affected patients, providing a new tool for researchers to study the disease and test potential therapies. The re-created neurons will help understand what disables and kills brain cells in people with HD.
A proposed drug treatment has shown promise in reversing Huntington's disease symptoms in animal models, with sustained motor and neurological benefits reported. The therapy silences the mutated gene responsible for the disease by using antisense oligonucleotides to destroy toxic proteins.
A new gene-silencing strategy has reversed core symptoms of Huntington's disease in animal models, suggesting a potential treatment approach for the neurodegenerative disorder. The therapy, involving antisense oligonucleotides, produced sustained benefits with minimal side effects.
A new study suggests that Coenzyme Q10 reduces oxidative damage in patients with Huntington's disease, hinting at its potential to slow progression. The discovery also identifies a new biomarker, 80HdG, which could be used to screen experimental treatments for this and other neurological disorders.
Researchers have developed a device that delivers a genetically engineered neurotrophic factor directly to the brain, treating neurological symptoms in laboratory rats. The study found significant protection against toxicity and reduced striatal lesion size, suggesting promising therapeutic potential for Huntington's disease.
A new study suggests that the toxic effects of the huntingtin protein on cells may not be driven exclusively by its length, but also by which other proteins are present in the cell. The researchers found that yeast cells containing human huntingtin protein with an expanded region exhibited toxicity differences based on the presence of ...
Researchers from South Korea, Sweden, and the US have successfully transplanted HD-induced pluripotent stem cells into animal models, exhibiting significant behavioral recovery. The study provides new insights into the underlying disease process and potential treatments for Huntington's disease.
Research suggests that individuals with polyglutamine (polyQ) diseases, including Huntington's disease, have a lower risk of developing cancer. This reduced cancer risk is thought to be due to the expansion of certain sequence repeats in specific genes, which impairs gene activity and leads to cell death.
A research team at the University of Melbourne has developed a novel technique to track diseased proteins in brain diseases like Huntington's and Alzheimer's. The technique uses a flow cytometer to rapidly identify and track protein clusters in cells, enabling drugs to be targeted at different stages of disease development.
A new study suggests that stem cells could potentially restore muscle coordination deficits in patients with Huntington's disease. Researchers successfully integrated human embryonic stem cells into mouse brains, reestablishing the broken communication network and restoring motor function.
A significant scientific discovery has been made in the fight against Huntington's disease, identifying specific enzymes called HDACs as positive agents for the mutation that underlies the disorder. Blocking these enzymes with experimental drugs greatly reduces the risk of further mutation.
Researchers at the University of Alberta have discovered a treatment that restores motor skills in lab models with Huntington disease by restoring normal levels of brain molecule GM1. The therapy has shown promise in improving cognitive symptoms as well, suggesting it could be effective for patients.
Researchers at UC Davis have developed a new approach using stem cells to deliver gene therapy specifically targeting the genetic abnormality found in Huntington's disease. By transferring inhibitory RNA sequences from donor cells into target neurons, they significantly decreased the synthesis of the abnormal huntingtin protein.
Researchers at Scripps Research have identified a compound that can repair specific defects in RNA, a key step in developing treatments for incurable diseases like Huntington's. The new technology targets toxic RNA defects associated with Spinocerebellar ataxia and Kennedy disease.
Researchers at UMass Amherst discover a key interaction for treating Fabry disease using small molecule chaperones like galactose and DGJ. These molecules help stabilize the faulty alpha-galactosidase enzyme, reducing symptoms and toxicity.
Treatment with Sirt1 overexpression may slow brain cell loss in Huntington's disease, a neurodegenerative disorder. Increased Sirt1 expression protected against neurodegeneration and huntingtin aggregation in mouse models.
The collaboration aims to build on Professor Susann Schweiger's discovery of the mechanism controlling disease-causing protein production. The project seeks to prevent toxic protein buildup in the brain and potentially provide a treatment for Huntington's Disease.
Researchers found that Dantrolene, a muscle relaxant, reduces the severity of walking and balance problems in mice with Huntington's disease. The drug prevents calcium-dependent toxicity in laboratory-grown neurons and protects coordination in mice with HD-like disease.
Pridopidine, a novel dopidine, appears well-tolerated and warrants further investigation for patients with Huntington's disease. The drug improved voluntary motor function and reduced chorea symptoms in a phase 3 trial.
Researchers at Gladstone Institutes discovered a protein form linked to Huntington's disease that influences symptom timing and severity. The study offers new avenues for treating not only Huntington's but also similar conditions like Alzheimer's and type 1 diabetes.
Researchers found that melatonin delayed the onset of symptoms by 19% and reduced mortality by 18% in a mouse model of Huntington's disease. The hormone was shown to target mitochondria, reducing programmed cell death, and increasing neuroprotection when administered.
Researchers from the University of Alberta and Cambridge have discovered a fifth adaptin protein complex involved in membrane trafficking, which has been present for billions of years. This finding opens up new avenues for understanding neurodegenerative diseases such as Alzheimer's, Huntington's disease, and ALS.
Researchers have discovered that normal Htt protein regulates the formation of cilia, which are longer and disorganized in patients with Huntington disease. This finding suggests that abnormal cilia may contribute to some symptoms of the disorder.
Researchers at Brigham and Women's Hospital and Massachusetts General Hospital have identified a transcriptional biomarker that may assist in the monitoring of Huntington's disease activity and the evaluation of new medications. The biomarker, H2AFY, is overexpressed in the blood of individuals with Huntington's disease.
Researchers at Harvard Medical School found that modulating Irs2 levels can slow HD progression by reducing nerve cell damage and increasing lifespan. Decreasing Irs2 levels attenuated symptoms of the disease.
The California Institute for Regenerative Medicine approved five UC Davis Health System teams with research planning grants worth up to $20 million each. These grants aim to develop human clinical trials for treatments of Huntington's disease, critical limb ischemia, airway disease, HIV/AIDS and osteoporosis.
Researchers at UT Southwestern Medical Center have identified compounds that inhibit a signaling pathway in Huntington's disease, a fatal genetic disorder. The quinazoline-derived compounds block the store-operated calcium entry signaling pathway, potentially slowing the progression of degenerative nerve disorders.
Johns Hopkins researchers have identified a natural mechanism to block the expression of the mutated gene causing HD, potentially slowing its progression. By manipulating a newly found 'brake' gene, they aim to stop or slow production of the toxic huntingtin protein.
Researchers have identified a compound called JM6 that diminishes the effects of both diseases in animal models, preventing memory deficits and loss of synaptic connections. The compound works by inhibiting an enzyme linked to neurodegenerative diseases, suggesting a potential therapeutic breakthrough.
Researchers have discovered a potential therapeutic strategy for Huntington's disease by targeting an enzyme in the brain. The study, published in Current Biology and Cell, found that inhibiting this enzyme can slow down neurodegeneration and improve symptoms.
Researchers at McMaster University have discovered a new drug target that may prevent the onset of Huntington's disease by restoring a critical chemical change in the huntingtin protein. The kinase inhibitor drugs work similarly to those used for heart diseases, and could potentially delay symptom onset.
Researchers have identified two gene classes associated with new prion formation in yeast, which may provide a genetic key to understanding neurodegenerative disorders like Creutzfeldt-Jakob and Huntington's disease. The study found that genes important for prion generation also increased toxicity in the presence of certain proteins.
Researchers developed a transgenic mouse model of the rare neurodegenerative disorder HDL2 to study its pathogenesis. The study found overlapping polyQ-mediated mechanisms with Huntington's disease and identified a novel expanded polyQ protein driving disease progression in HDL2 mice.
Researchers found that the process of repairing damaged DNA repeats can lead to cell death in yeast, providing insight into neurodegenerative diseases. The study suggests that expanded DNA repeats can be toxic to cells, contributing to disease progression.
Researchers at Lund University have discovered a causal relationship between mutated Huntington's protein and weight gain in mice. The study shows significant changes in the brain's hormone control centre, leading to insulin resistance and metabolic dysfunction.
A new study reveals that Huntington's disease protein causes metabolic imbalances in the hypothalamus, leading to increased appetite and weight. The research provides evidence of a causal link between mutant huntingtin expression and metabolic dysfunction.
Protein folding is a crucial process in the body, but misfolding can lead to debilitating neurodegenerative diseases. Stanford researchers have discovered a new mechanism for protein folding that could aid in developing therapies for these conditions. By studying the chaperonin TRiC, they found that proteins are released from the foldi...
Researchers found that a protein called DRP1 triggers a chain reaction causing brain nerve cells to die, but toning it down prevents the chain reaction and keeps those cells alive. The study aims to test whether this protein also protects the brain, potentially delaying disease onset.
Researchers from the University of Leicester and international partners have identified potential new therapeutic targets for Huntington's disease using cutting-edge genetic techniques. The study found that flavonoids can prevent cell death in yeast, suggesting a possible new treatment approach.
Researchers developed a gene therapy strategy using parthenogenetic embryonic stem cells, which can differentiate into multiple tissue types and potentially reduce rejection problems. The approach shows promise for treating autosomal dominant diseases like Beta Thalassemia, tuberous sclerosis, or Huntington's disease
Researchers at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that protect brain cells against nerve-degenerative diseases. The compounds, developed by SMU and UT Dallas scientists, showed promise in tissue culture models and animal models of neurodegeneration.
A new study has identified promising biomarkers for Huntington's disease that could be used to track disease progression and test potential disease-modifying treatments. Biomarkers were found in brain imaging techniques, including whole-brain and striatal atrophy, which increased at a higher rate in individuals with the disease.
Researchers at the Salk Institute found that fisetin slows the onset of motor problems and delays death in three models of Huntington's disease. The study suggests that fisetin may be able to slow down the progression of the disease in humans, improving quality of life for those affected.